A novel hypergraph model for identifying and prioritizing personalized drivers in cancer
Fig 6
The survival curves for subtyping BRCA, KIRC, and LIHC using the gene expression data.
(A) In different cancer types, the expression data of known tumor-specific drivers with mutation frequency ≥ 2% were used in subtyping patients. Different subtypes (S1, S2,…) are indicated by different colored lines. (B-D) The similar analysis based on expression data of genes that are known tumor-specific drivers with mutation frequency < 2%, predicted driver genes with mutation frequency ≥ 2%, and predicted driver genes with mutation frequency < 2% respectively.